Work

Osteoporosis Therapy: Bone Modeling during Growth and Aging

Year: 2017

Type: article

Abstract: TABLE 1 | Expected effects of anabolic osteoporosis agents on bone modeling.Anabolic osteoporosis agents Bone modeling Clinical status parathyroid hormone Teriparatide Daily (20 μg/day) a + Approval Weekly (56.5 μg/week) a + Approval b parathyroid hormone-related protein Abaloparatide (daily, 80 μg/day) a ++ Phase 3 Anti-sclerostin antibody Romosozumab (monthly, 210 mg/month) a +++ Phase 3 a Subcutaneous injection.

Source: Frontiers in Endocrinology

DOI: 10.3389/fendo.2017.00046

Authors: Toshihiro Sugiyama, Hiromi Oda

Institution: Saitama Medical University

Language: English

Topic: Bone health and osteoporosis research

Subfield: Orthopedics and Sports Medicine

Field: Medicine

Domain: Health Sciences

SDG: Good health and well-being

Open Access status: gold

Estimated APC paid: $3,801